Noah Goodman Sells 3,389 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Noah Goodman sold 3,389 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $114.29, for a total transaction of $387,328.81. Following the completion of the transaction, the insider directly owned 47,179 shares of the company’s stock, valued at approximately $5,392,087.91. This represents a 6.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Noah Goodman also recently made the following trade(s):

• On Thursday, June 25th, Noah Goodman sold 5,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $114.00, for a total transaction of $570,000.00.
• On Monday, June 22nd, Noah Goodman sold 2,500 shares of Kymera Therapeutics stock. The shares were sold at an average price of $99.00, for a total transaction of $247,500.00.
• On Tuesday, April 14th, Noah Goodman sold 1,347 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.00, for a total transaction of $121,230.00.
• On Friday, April 10th, Noah Goodman sold 2,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $87.35, for a total transaction of $174,700.00.
• On Thursday, April 9th, Noah Goodman sold 8,264 shares of Kymera Therapeutics stock. The stock was sold at an average price of $87.50, for a total transaction of $723,100.00.

Kymera Therapeutics Stock Performance

Shares of NASDAQ:KYMR opened at $113.51 on Friday. The firm has a market capitalization of $9.34 billion, a PE ratio of -31.80 and a beta of 1.95. Kymera Therapeutics, Inc. has a 52-week low of $36.65 and a 52-week high of $130.05. The firm has a fifty day moving average of $87.36 and a 200 day moving average of $83.12.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The business had revenue of $34.37 million for the quarter, compared to the consensus estimate of $8.27 million. During the same quarter last year, the business posted ($0.82) earnings per share. The company’s revenue for the quarter was up 55.5% on a year-over-year basis. On average, sell-side analysts forecast that Kymera Therapeutics, Inc. will post -3.28 EPS for the current fiscal year.

Key Headlines Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Seeking Alpha upgraded Kymera Therapeutics to Buy, citing strong pipeline progress, a roughly $1.5 billion cash position, and accelerated timing for KT-621 Phase 2b topline data by year-end 2026. The article argues the oral STAT6 degrader could compete in a large atopic dermatitis market and challenge injectable therapies. Article Title
• Positive Sentiment: Another Seeking Alpha note said Kymera is building toward a key 2H 2026 inflection point, with KT-621’s Phase 2b readout seen as a major catalyst. The commentary also highlighted rapid enrollment, a strong balance sheet, and possible partnership upside. Article Title
• Neutral Sentiment: Analysts continue to rate KYMR favorably overall, with the consensus still at Moderate Buy and recent target increases from firms including Truist and Canaccord Genuity suggesting confidence in the company’s pipeline and long-term prospects.
• Negative Sentiment: Recent insider sales from CEO Nello Mainolfi, CFO Bruce N. Jacobs, and insider Noah Goodman may weigh on sentiment, as the transactions were sizable and follow additional selling earlier in the quarter. Article Title

Institutional Investors Weigh In On Kymera Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. US Bancorp DE boosted its holdings in Kymera Therapeutics by 9.8% during the 3rd quarter. US Bancorp DE now owns 1,865 shares of the company’s stock valued at $106,000 after acquiring an additional 166 shares during the period. Glenmede Trust Co. NA increased its stake in Kymera Therapeutics by 3.6% in the 1st quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock worth $565,000 after purchasing an additional 235 shares during the period. Cetera Investment Advisers increased its stake in Kymera Therapeutics by 7.5% in the 1st quarter. Cetera Investment Advisers now owns 3,602 shares of the company’s stock worth $300,000 after purchasing an additional 252 shares during the period. Larson Financial Group LLC increased its stake in Kymera Therapeutics by 36.9% in the 4th quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock worth $83,000 after purchasing an additional 287 shares during the period. Finally, Swiss National Bank lifted its position in Kymera Therapeutics by 0.3% in the first quarter. Swiss National Bank now owns 94,500 shares of the company’s stock valued at $7,871,000 after purchasing an additional 300 shares during the last quarter.

Analyst Ratings Changes

A number of research firms recently weighed in on KYMR. Morgan Stanley restated an “overweight” rating and issued a $119.00 target price on shares of Kymera Therapeutics in a research report on Thursday, April 30th. Loop Capital set a $97.00 price target on shares of Kymera Therapeutics in a research report on Monday, June 8th. Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Canaccord Genuity Group boosted their price objective on shares of Kymera Therapeutics from $106.00 to $129.00 and gave the stock a “buy” rating in a report on Friday, June 26th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $134.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, June 25th. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $121.41.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.